InfuSystems Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
$INFU
Medical/Dental Instruments
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 16, 2024
___________________________________
(Exact name of registrant as specified in its charter)
___________________________________
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification Number) | ||||||
(Address of principal executive offices) (Zip Code) | ||||||||
( | ||||||||
(Registrant's telephone number, including area code) | ||||||||
| Not Applicable | ||||||||
| (Former Name or Former Address, if Changed Since Last Report) | ||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on which Registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 - Submission of Matters to a Vote of Security Holders
At the 2024 Annual Meeting of Stockholders of InfuSystem Holdings, Inc. (the "Company") held on May 16, 2024 , the matters voted upon and the number of votes for, against or withheld, as well as the number of abstentions and broker non-votes as to such matters, were as stated below:
Proposal No. 1:
The Company's Board Nominees
For | Withheld | Broker Non-Votes | |||||||||
Ralph Boyd | 10,321,961 | 5,543,688 | 2,409,394 | ||||||||
Richard DiIorio | 12,564,229 | 3,301,420 | 2,409,394 | ||||||||
| Kenneth Eichenbaum | 11,444,647 | 4,421,002 | 2,409,394 | ||||||||
Paul Gendron | 11,366,680 | 4,498,969 | 2,409,394 | ||||||||
| Beverly Huss | 10,958,717 | 4,906,932 | 2,409,394 | ||||||||
Carrie Lachance | 12,443,248 | 3,422,401 | 2,409,394 | ||||||||
Scott Shuda | 9,810,697 | 6,054,952 | 2,409,394 | ||||||||
All seven of the Company's Board nominees (Messrs. Boyd, DiIorio, Eichenbaum, Gendron and Shuda and Mss. Huss and Lachance) were elected to the Board.
Proposal No. 2:
The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's proxy statement as follows:
For | Against | Abstain | Broker Non-Votes | ||||||||
| 8,447,458 | 7,411,428 | 6,763 | 2,409,394 | ||||||||
Proposal No. 3:
The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's registered independent accounting firm for the fiscal year ending December 31, 2024 as follows:
For | Against | Abstain | Broker Non-Votes | ||||||||
| 16,164,598 | 1,930,216 | 180,229 | 0 | ||||||||
Item 9.01 - Financial Statements and Exhibits
(d) Exhibits
| Exhibit No. | Description | |||||||
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |||||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INFUSYSTEM HOLDINGS, INC. | |||||
By: | /s/ Barry Steele | ||||
| Barry Steele | |||||
| Chief Financial Officer | |||||
Dated: May 17, 2023